Real-World Data to Support First-Line Treatment Strategy

Pfizer (PFE) has launched the LOREA observational study (NCT06487078) to evaluate the efficacy and safety of lorlatinib (brand names 'Lorbrena'/'Lorbqua'), a third-generation anaplastic lymphoma kinase (ALK) inhibitor, in treatment-naïve patients with ALK-positive non-small cell lung cancer (NSCLC) in a real-world setting in France. Unlike the strictly controlled Phase 3 CROWN trial, this study is designed to validate treatment outcomes in a more diverse patient population, including those with comorbidities or who are elderly. A key objective is to demonstrate that the previously observed progression-free survival (PFS) benefit can be replicated in a broader patient population, thereby maintaining the drug's commercial value.

Enhanced Blood-Brain Barrier Penetration and Addressing Unmet Needs

Lorlatinib is a third-generation targeted therapy designed with enhanced blood-brain barrier (BBB) penetration compared to first-generation crizotinib (brand name 'Xalkori') and second-generation alectinib (brand name 'Alecensa'). Up to 40% of patients with ALK-positive NSCLC experience central nervous system (CNS) metastasis at diagnosis or during treatment, leading to a significantly worsened prognosis. Lorlatinib has demonstrated strong intracranial objective response rates (IC-ORR) in these patients, successfully addressing the unmet need for effective brain metastasis control. The French LOREA study will also focus on monitoring the drug's ability to control brain metastases by setting intracranial progression-free survival and quality of life (QoL) as key secondary endpoints.

Competitive Landscape in the Global ALK Inhibitor Market

The ALK-positive NSCLC market is currently shifting from a landscape dominated by Roche's alectinib and Takeda's brigatinib (brand name 'Alunbrig'), which are second-generation drugs, to one increasingly influenced by Pfizer's third-generation lorlatinib. In 2025, the market size for ALK-positive NSCLC in the major seven countries (7MM), including the United States, Europe (four countries), the United Kingdom, and Japan, is estimated at approximately $2.05 billion. Lorbrena has achieved strong clinical results, generating global sales of $473 million in the first half of 2025, representing a 42% year-over-year increase. The industry anticipates that the accumulation of real-world data from this study will help solidify lorlatinib's position as a standard of care (SoC) in the conservative European market.

Emergence of Next-Generation Competitors and the Importance of Long-Term Survival Data

To maintain its leading position, lorlatinib requires the accumulation of long-term real-world data, as new competitors are emerging. Nuvalent is developing neladalkib (developmental code 'NVL-655'), a next-generation ALK inhibitor, with the goal of overcoming lorlatinib resistance and entering the market. To counter this, Pfizer must demonstrate in real-world settings the robust PFS data observed in the seven-year long-term follow-up study. The LOREA study, which began in January 2025, will enroll 90 patients and is expected to be completed in November 2028. The cumulative data collected during this period will serve as a milestone in building Pfizer's oncology portfolio defense.